Norway Influenza Treatment Market Size & Outlook

The influenza treatment market in Norway is expected to reach a projected revenue of US$ 89.6 million by 2030. A compound annual growth rate of 1.7% is expected of Norway influenza treatment market from 2025 to 2030.
Revenue, 2024 (US$M)
$81.0
Forecast, 2030 (US$M)
$89.6
CAGR, 2025 - 2030
1.7%
Report Coverage
Norway

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Norway influenza treatment market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Norway influenza treatment market highlights

  • The Norway influenza treatment market generated a revenue of USD 81.0 million in 2024 and is expected to reach USD 89.6 million by 2030.
  • The Norway market is expected to grow at a CAGR of 1.7% from 2025 to 2030.
  • In terms of segment, oseltamivir phosphate was the largest revenue generating treatment in 2024.
  • Baloxavir Marboxil is the most lucrative treatment segment registering the fastest growth during the forecast period.


Influenza treatment market data book summary

Market revenue in 2024USD 81.0 million
Market revenue in 2030USD 89.6 million
Growth rate1.7% (CAGR from 2025 to 2030)
Largest segmentOseltamivir phosphate
Fastest growing segmentBaloxavir Marboxil
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPeramivira, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate
Key market players worldwideNovartis AG ADR, Roche Holding AG, BioCryst Pharmaceuticals Inc, Sanofi SA, GSK PLC, GSK PLC ADR, Viatris Inc, Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Co Ltd, AstraZeneca PLC


Other key industry trends

  • In terms of revenue, Norway accounted for 1.3% of the global influenza treatment market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany influenza treatment market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 522.6 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Influenza Treatment Market Companies

Name Profile # Employees HQ Website
BioCryst Pharmaceuticals Inc View profile 531 4505 Emperor Boulevard, Suite 200, Durham, NC, United States, 27703 https://www.biocryst.com
Daiichi Sankyo Co Ltd View profile 17435 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 https://www.daiichisankyo.com
Viatris Inc View profile 38000 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 https://www.viatris.com
AstraZeneca PLC View profile 89900 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA https://www.astrazeneca.com
GSK PLC View profile 70200 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS https://www.gsk.com
Roche Holding AG View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com
GSK PLC ADR View profile 70200 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS https://www.gsk.com
Sanofi SA View profile 87994 46, avenue de la Grande Armée, Paris, France, 75017 https://www.sanofi.com
Teva Pharmaceutical Industries Ltd View profile 37851 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 https://www.tevapharm.com
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com

Norway influenza treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza treatment market will help companies and investors design strategic landscapes.


Oseltamivir phosphate was the largest segment with a revenue share of 28.15% in 2024. Horizon Databook has segmented the Norway influenza treatment market based on peramivira, zanamivir, baloxavir marboxil, oseltamivir phosphate covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Norway influenza treatment market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Norway influenza treatment market databook

  • Our clientele includes a mix of influenza treatment market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Norway influenza treatment market , including forecasts for subscribers. This country databook contains high-level insights into Norway influenza treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Norway Treatment - Influenza Treatment Market size, 2024 - 2030 (US$M)

Norway Influenza Treatment Market Outlook Share, 2024 & 2030 (US$M)

Norway Treatment - Influenza Treatment Market size, 2024 - 2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online